Kineta Inc. Announces Regulatory Clearance to Initiate a Phase 1 Clinical Trial for ShK-186
Published: Aug 21, 2012
SEATTLE--(BUSINESS WIRE)--Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel. Kineta’s program is the first Kv1.3-specific inhibitor advanced into the clinic, a key milestone in the industry’s race to develop an immune-sparing therapy for a spectrum of diseases that includes Multiple Sclerosis (MS), Rheumatoid Arthritis (RA) and Lupus (SLE).